Breaking News

Wegovy improves function in certain heart failure patients

August 25, 2023
Annalisa-Merelli-avatar - light bg
General Assignment Reporter
Buongiorno! Annalisa Merelli here, doing her best to fill in for the uncomparable Liz Cooney. Another trial showing Wegovy's cardiovascular benefits is just the first of the news we have for you on this fine Friday, so let's dive right in.

cardiovascular disease

Second trial shows Wegovy can improve heart health

A study published today in NEJM found that the weight loss drug Wegovy led to significant improvements in symptoms and physical function for people with obesity and heart failure with preserved ejection fraction, or HFpEF, a condition making up an estimated half of all heart failure cases. Only weeks ago, a landmark study by Novo Nordisk had found Wegovy had impressive benefits on cardiovascular health

Unlike current treatments for HFpEF, which reduce the risk of hospitalization and death but haven't shown as much of a benefit for physical function, Wegovy improved the daily quality of life of patients, who experience fatigue and shortness of breath that can compromise their ability to perform tasks. The trial also contributes to the overall understanding of HFpEF, supporting the notion that obesity isn't a comorbidity of HFpEF, but its driver. More here from my colleague Elaine Chen. 


infectious disease

How health officials plan to cope with respiratory virus season

Covid isn't seasonal yet, but respiratory virus season is almost upon us. At a briefing yesterday, CDC and FDA officials laid out their plan for Covid countermeasures — alongside those for RSV and influenza — starting with a vaccine rollout in mid-September. "We are in our strongest position yet to be able to fight Covid-19 as well as the other viruses that are responsible for the majority of fall and winter hospitalizations," one CDC official said.

The Covid boosters will be monovalent, and for the first time will no longer target the original strand of the virus, from late 2019. As was the case last year, a second dose will also be available for older adults and immunocompromised people. The booster's efficacy against the latest Covid subvariant hasn't been sufficiently tested yet. At-home Covid tests are being shipped to schools, libraries, long-term care facilities, and other distribution points, and may even be sent to households via USPS again, if necessary. STAT's Helen Branswell has more.


Health care

What AAP's gender-affirming care evidence review actually means

The American Academy of Pediatrics has reaffirmed its support of gender-affirming care with its recent announcement that it's conducting a review of current evidence. Far from an attempt to curtail access or limit options, the AAP says the review is a way to stay up to date with the latest scientific evidence and hone best practices, especially as gender-affirming care becomes even more of a political lightning rod. 

Experts also think comparing the American landscape with Europe's is misleading: Many European policy interventions have been portrayed as restricting gender-affirming care for minors, when they are rather changes to how care is accessed. In the U.S., on the other hand, bans on gender-affirming hormones, surgery, or both for youth have been passed in nearly half of states, though federal judges have blocked some. Read more.



Closer Look

What happened when NYU launched a private ChatGPT for its health data

Courtesy Joe Carrotta/NYU Langone

A fourth-year medical student, a music therapist, a child psychiatrist, and a physician-researcher join a "prompt-a-thon" — this is not the beginning of a joke, but the setup for NYU Langone's experiment in using ChatGPT. They were among 70 participants at a workshop set up to familiarize NYU's staff with its HIPAA-compliant version of the OpenAI technology, and the potential it offers. 

For the foursome, the task was to use ChatGPT around the theme of equity. AI was not great at it: It couldn't identify instances of bias in the text of the patient record, nor could it exhaustively identify them in a research article assessing Covid-19 disparities. But that was precisely the point of the exercise: to educate health care providers  about the opportunities presented by generative AI technology as well as its limitations. STAT's Mario Aguilar followed the workshop, and has the story.


environmental health

Canadian wildfire smoke led to rise in U.S. ER visits for asthma

Smoke from Canada's wildfires affected the U.S. from late April until early August this year, and a new CDC report found that over a 19-day period, asthma-associated emergency department visits in the country were 17% more than expected for the age group and region where they occurred. The report, which also found increased asthma visits in the days following the wildfire smoke, in particular among children, provides quantitative evidence of how wildfire smoke can negatively impact respiratory health.

In New York state, where the air quality was compromised by wildfire smoke from June 6-8, the increase in asthma-related ER visits was especially striking. On June 7, there were 147 visits statewide, or nearly 82% more than on average from June 1-5 (81 a day), prior to the smoke setting in. Eastern Lake Ontario registered the largest increase, 179%, and all regions except the Adirondacks registered at least a 35.5% increase. Young people were especially affected: Asthma-related visits for people ages 10 to 29 were up almost 198% on June 7 compared to the June 1-5 average.


Covid-19

Study reinforces how pulse oximeters delayed Covid care for Black patients

STAT's Usha Lee McFarling has this report: Black patients experienced delays in receiving Covid-19 treatment because of pulse oximeters that overestimated the amount of oxygen in their blood, research published yesterday in JAMA Network Open has found. The study of nearly 25,000 patients adds to the evidence that pulse oximeters may harm patients with darker skin because they aren't as accurate for them, and may lead doctors to undertreat them. "Pulse oximeter inaccuracies are central to the racial and ethnic differences in receipt of Covid-19 therapies," the researchers wrote. 

They also found hospital readmissions were higher among patients whose need for Covid-19 treatment was not initially recognized, though they said it was unclear if this was due to delayed treatment or other factors. While the study found inaccuracies were higher for patients with darker skin, researchers said inaccuracies in the devices also delayed treatment for white patients, suggesting clinicians should be mindful of potential errors that could impact all patients.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Nonprofit health system ends practice of denying care to patients in debt, New York Times
  • Drugmakers already bet big on mRNA for cancer. Why is Biden going in, too? STAT
  • Abortion opponents are targeting a signature GOP public-health initiative, The New Yorker
  • Lockdowns and face masks really did help to control Covid-19, New Scientist
  • Opinion: Australia's human-centric approach to dialysis, STAT

Thanks for reading! Hope you have a great weekend! — Annalisa


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments